N. Mccabe

发表

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Alan Ashworth, Ian Hickson, Nuala McCabe, 2005, Nature.

Uncovering BRCA1-regulated signalling pathways by microarray-based expression profiling.

P. Mullan, D. Harkin, J. Quinn, 2001, Biochemical Society transactions.

Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer

A. Ashworth, M. Cerone, C. Lord, 2009, Oncogene.

IGF-1R inhibition sensitizes breast cancer cells to ATM-related kinase (ATR) inhibitor and cisplatin

R. O'Connor, R. Kennedy, C. O’Flanagan, 2016, Oncotarget.

R. O'Connor, R. Kennedy, C. O’Flanagan, 2018, Oncogene.

Topoisomerase II inhibitors induce cGAS-STING dependent inflammation resulting in cytokine induction and immune checkpoint activation

R. Greenberg, R. Kennedy, D. Harkin, 2019, bioRxiv.

Potentiation of inflammatory CXCL8 signalling sustains cell survival in PTEN-deficient prostate carcinoma.

M. Salto‐Tellez, C. Albanese, R. Kennedy, 2013, European urology.

A Novel Role for Cathepsin S as a Potential Biomarker in Triple Negative Breast Cancer

D. McArt, R. O'Connor, R. Kennedy, 2019, Journal of oncology.

BRCA1 Interacts with and Is Required for Paclitaxel-Induced Activation of Mitogen-Activated Protein Kinase Kinase Kinase 3

E. Liu, P. Johnston, R. Kennedy, 2004, Cancer Research.

Mechanistic Rationale to Target PTEN-Deficient Tumor Cells with Inhibitors of the DNA Damage Response Kinase ATM.

R. Kennedy, D. Harkin, Clark C. Chen, 2015, Cancer research.

OP-JNCI160221 1..10

M. Salto‐Tellez, R. Kennedy, P. Mullan, 2016 .

BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly (ADP-ribose) polymerase: An issue of potency

A. Ashworth, A. Tutt, C. Lord, 2005, Cancer biology & therapy.

Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer.

A. Ashworth, A. Tutt, S. Jackson, 2005, Cold Spring Harbor symposia on quantitative biology.

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.

Alan Ashworth, Nuala McCabe, A. Ashworth, 2006, Cancer research.

Development of PARP Inhibitors for BRCA-Deficient Epithelial Ovarian Cancer

R. Kennedy, N. Mccabe, E. Parkes, 2018, Oncogenomics.

DNA Polymerases as Potential Therapeutic Targets for Cancers Deficient in the DNA Mismatch Repair Proteins MSH2 or MLH1

A. Ashworth, D. Burgess, Y. Nakabeppu, 2010, Cancer cell.

DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy

R. Kennedy, N. Mccabe, E. Parkes, 2019, Journal of oncology.

X-Chromosome Inactivation: X Marks the Spot for BRCA1

A. Ashworth, N. Mccabe, C. Stone, 2003, Current Biology.

Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer

I. McNeish, R. Kennedy, P. Mullan, 2017, Oncotarget.

Defining the molecular evolution of extrauterine high grade serous carcinoma.

Alan R Gilmore, Aideen C Roddy, M. Salto‐Tellez, 2019, Gynecologic oncology.

Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer

M. Salto‐Tellez, R. Kennedy, P. Mullan, 2016, Journal of the National Cancer Institute.

BRCA1 Regulates the Interferon γ-mediated Apoptotic Response*

D. Haber, P. Johnston, B. Koller, 2002, The Journal of Biological Chemistry.

BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents

E. Liu, D. Haber, P. Johnston, 2001, Oncogene.

Prior knowledge transfer across transcriptional data sets and technologies using compositional statistics yields new mislabelled ovarian cell line

T. Davison, T. Delaney, C. Gourley, 2016, Nucleic acids research.

PP 74 A subtype representing activated ATM signalling in PTEN-null tumours

R. Kennedy, D. Harkin, N. Goffard, 2011 .

When the guardian becomes the enemy: Targeting ATM in PTEN-deficient cancers

R. Kennedy, N. Mccabe, S. Walker, 2016, Molecular & cellular oncology.

miR-191 promotes radiation resistance of prostate cancer through interaction with RXRA.

I. Mills, P. Boutros, Jouhyun Jeon, 2019, Cancer letters.

ATM Kinase Inhibition Preferentially Sensitises PTEN-Deficient Prostate Tumour Cells to Ionising Radiation

R. Kennedy, K. Butterworth, K. Prise, 2020, Cancers.

BRCA1 regulates the interferon gamma-mediated apoptotic response.

D. Haber, P. Johnston, B. Koller, 2002, The Journal of biological chemistry.

AXL Mediates Resistance to AKT inhibition in Oesophageal Adenocarcinoma.

R. Turkington, R. Kennedy, N. Mccabe, 2017 .

A strong correlation between expression of Wntless and of human epidermal growth factor receptor 2 in gastric, ovarian, and breast cancers suggests a novel-signalling pathway involving NFκB and STAT3

M. Salto‐Tellez, D. McArt, P. Tan, 2013, The Lancet.

Abstract 3787: Exploring the effect of chemotherapies on STING-dependent cytokine release

R. Kennedy, N. Mccabe, E. Parkes, 2018, Immunology.

The role of PTEN as a cancer biomarker

R. Kennedy, K. Prise, N. Mccabe, 2016, Oncoscience.

Exploration of the cGAS-STING pathway in prostate cancer.

R. Kennedy, D. Harkin, N. Mccabe, 2018 .

Role played by BRCA1 in regulating the cellular response to stress.

R. Kennedy, P. Mullan, D. Harkin, 2001, Biochemical Society transactions.

Mechanistic Rationale to Target PTEN-Deficient Tumor Cells with Inhibitors of the DNA Damage Response Kinase ATM.

R. Kennedy, D. Harkin, Clark C. Chen, 2015, Cancer Research.

BRCA1 Regulates the Interferon (cid:1) -mediated Apoptotic Response*

D. Haber, P. Johnston, B. Koller, 2002 .

An evaluation of siRNA screening in identification of targets in PTEN deficient tumor cells.

T. Davison, T. Delaney, G. Jellema, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.